Search alternatives:
significant larger » significantly larger (Expand Search), significant barrier (Expand Search), significant dangers (Expand Search)
larger decrease » marked decrease (Expand Search)
point decrease » point increase (Expand Search)
Showing 1 - 20 results of 4,899 for search '(( significant larger decrease ) OR ( significant ((mean decrease) OR (point decrease)) ))', query time: 0.51s Refine Results
  1. 1
    Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session.

    Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Cephalometric measurement points.

    Cephalometric measurement points. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Mean ± SD of the different parameters relative to bipedal stance on soft support with the eyes open recorded in the Chewing and Hand Grip groups.

    Mean ± SD of the different parameters relative to bipedal stance on soft support with the eyes open recorded in the Chewing and Hand Grip groups. by Cristina Dolciotti (16317330)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Middle cerebral artery mean flow velocity at three time points.

    Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 6
    PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity.

    PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

    Published 2025
    Save to List
    Saved in:
  7. 7
    The mean and standard deviation of parameters.

    The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 8
    Average stability values (mean ± standard deviation) and statistical results.

    Average stability values (mean ± standard deviation) and statistical results. by Hyung Suk Yang (20442438)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 9
    Socio-demographic characteristics of women in study sample (means except as noted).

    Socio-demographic characteristics of women in study sample (means except as noted). by Chelsea Ducille (21540080)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: